BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $42.11M (cash outflow) rose 8539.0% year over year, ahead of the +1029.3% change in trailing-twelve-month net income. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +3264.4% a year.
Context
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$69.83M (-47.9%) for the fiscal year ending Dec 2026, a step up from the -1863.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$42.11M+8.5% QoQ
- Last fiscal yearDec 2025
- -$134.04M-1863.9% YoY
- LTMMar 2026
- -$154.1M+1029.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (134.04M) USD
- Year-over-year change
- -1863.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (134.04M) | -1863.9% |
| FY2024 | 2024-12-31 | 7.6M | +18327.7% |
| FY2023 | 2023-12-31 | (41.69K) | -1084.4% |
| FY2022 | 2022-12-31 | (3.52K) | -4635.9% |
| FY2021 | 2021-12-31 | (74) | — |
Net Income vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1029.3% is the highest of 10, against a peer median of -3.8%.
- Over three fiscal years its annual growth of +3264.4% compares with a peer median of +12.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $294.88M USD | +220.5% | +13.6% | 42.0% | |
| LTM Sep 2026 | $246.76M USD | +13.5% | -11.7% | — | |
| LTM Sep 2026 | $208M USD | +106.9% | -2.1% | — | |
| LTM Mar 2026 | $157.3M USD | -54.5% | +3.8% | 76.8% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $154.1M USD | +1029.3% | +3264.4% | — |
| LTM Mar 2026 | $133.23M USD | -3.8% | +11.8% | 94.8% | |
| LTM Mar 2026 | CHF 94.54M CHF | -8.3% | +34.7% | 18758.0% | |
| LTM Jun 2026 | $71.19M USD | -60.8% | +18.5% | 67.8% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $59M USD | +0.3% | +20.9% | 61.3% |
| LTM Mar 2026 | $26.79M USD | -81.0% | — | 11.5% | |
| Peer median (excluding BBOT) | — | -3.8% | +12.7% | 67.8% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (74) | (3.52K) | (41.69K) | 7.6M | (134.04M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M |
| Change in Working Capital | 0 | 0 | 15K | (104.61K) | 6.43M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 172.52K | (1.84M) |
| Other Working Capital | 0 | 0 | 15K | (277.13K) | 8.27M |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | (8.53M) | 7.23M |
| Operating Cash Flow | 0 | 0 | (52.08M) | (763.82K) | (113.89M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (606K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (184M) | (83.93M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 157.86M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (184M) | 73.33M |
| Debt Repayment | 0 | 0 | 0 | (209.85K) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 187.25M | 395.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (578.55K) | (12.32M) |
| Financing Cash Flow | 0 | 0 | 0 | 186.46M | 383.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 0 | 225K | 1.7M | 342.84M |
| Free Cash Flow | 0 | 0 | (52.49M) | (763.82K) | (114.5M) |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.